



Zeal & Innovation in Medicine

Ref No.: ZLL/BM/BSE

Date : 04.08.2020

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai- 400 001
Company Code- 541400

Dear Sir,

Sub : Outcome of Board Meeting.

Ref : Our Notice dt. 28.07.2020

This is to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved:

- 1) Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2020.
- 2) Reappointment of Walker Chandiook and Co. LLP, as Statutory Auditor for the term of five years commencing from F.Y. 2020-21 subject to the approval of Shareholders of the Company in the Annual General Meeting.

The Board Meeting commenced at 03.00 p.m. and concluded at 05.30 p.m.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer



Encl : As above.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Nelson Square,
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118,271470
+091.712.2588070

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT,

Nagpur – 440013. Maharashtra, India. Ph.

Notes :

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 August 2020. There are no qualifications in the limited review report issued for the quarter ended 30 June 2020.
- 2) These financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under the Companies (Ind AS) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- 3) The figures for the quarter ended 31 March 2020 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2020 and the unaudited year to date figures upto 31 December 2019, on which auditors had performed a limited review.
- 4) The Company is principally engaged in a single business segment which is "pharmaceuticals".
- 5) Trade receivables outstanding as at 30 June 2020, include balances aggregating Rs.914.88 lakhs from customers situated outside India. These balances are outstanding for a period, beyond the timelines stipulated vide FED Master Direction No. 16/2015-16, under the Foreign Exchange Management Act, 1999. The Company is in the process of recovering the outstanding dues. The amount of fine/penalty, if any, that may be levied, is currently unascertainable but is not expected to be material and accordingly, the accompanying standalone financial results do not include any consequential adjustments that may arise due to such delay/default.
- 6) Deferred tax credit for the quarter ended 30 June 2019 and year ended 31 March 2020, includes credit due to impact of applicable tax rates from 34.94% to 29.12% on net deferred tax liabilities (excluding MAT Credit Entitlement Assets) as at 1 April 2019.

Place: Nagpur
Date: 04 August 2020


Anwar S. Daud
Managing Director

